Tumor-induced local and systemic immune suppression is commonly seen in patients with advanced malignancies. It is mediated by a variety of tumor-driven mechanisms, among which is the targeted apoptosis of effector T cells. 1 In previous studies we observed a high level of apoptosis in tumor-infiltrating lymphocytes and T lymphocytes in the peripheral circulation of head and neck squamous-cell carcinoma (HNSCC) and melanoma patients. 2, 3 We demonstrated that CD8 þ T cells are more sensitive to apoptosis than CD4 þ cells, and that the effector and tumor-specific subpopulations of CD8 þ T cells are preferentially targeted for apoptosis. 4 We and others have associated apoptosis of these antitumor effector cells with expression of FasL on the surface of tumor cells. 5 Many human tumors express FasL and can eliminate activated Fas þ effector lymphocytes through the Fas/FasL pathway. 6 FasL expression on tumor cells of different origin has been shown to correlate with patient prognosis negatively. 7, 8 Tumors can release membraneassociated FasL through secretion of microvesicles (MV), thereby providing an explanation for spontaneous apoptosis of T lymphocytes observed in the peripheral circulation of patients with cancer. [9] [10] [11] We showed previously that MV detected in sera of patients with oral carcinoma induced caspase-3 cleavage, DNA fragmentation, cytochrome c release, loss of mitochondrial membrane potential (MMP) and TCRz-chain downregulation in activated T lymphocytes. 11 Thus, the activity of tumor-derived MV might significantly contribute to the dysfunction and death of effector T cells in cancer patients. The loss of these cells could be responsible for inadequate antitumor function, and by extension, for inadequate immune responses to cancer vaccines.
The immunotherapeutic agent IRX-2 is a multitarget biologic agent containing physiological quantities of IL-1b, IL-2, IL-6, IL-8, GM-CSF, interferon-g (IFNg) and tumor necrosis factor-a (TNFa). Initial clinical trials have shown that IRX-2-based immunotherapy in HNSCC patients increased both apparent disease-free survival and overall survival Interestingly, we found that IRX-2 was effective not only against MV-induced apoptosis, but also provided protection to Jurkat cells against FasL-induced (CH-11 Ab) and cytotoxic drug-induced (staurosporine) apoptosis (Figure 1c and d) .
IRX-2-mediated protection from MV-or CH-11 Abinduced apoptosis was also observed when using primary blood-derived CD8 þ and CD4 þ T lymphocytes, as indicated by decreases in caspase activation (Table 1) and ANX binding (data not shown) in these T cells. CD8
þ T cells showed a significantly greater sensitivity to MV-induced apoptosis than CD4 þ T cells, but in both subsets, IRX-2 pretreatment provided protection against MV-induced apoptosis (Table 1) . Taken together, these findings indicate that IRX-2 can effectively protect primary T cells and T-cell lines not only from MV-or anti-Fas Ab-induced apoptosis but also from intrinsic apoptosis associated with staurosporine-induced mitochondrial changes.
IRX-2-mediated protection from apoptosis is time and concentration dependent. CD8
þ Jurkat cells were next preincubated with IRX-2 for various time periods or with increasing concentrations of IRX-2 and subsequently treated with MV for 3 h (Figure 1e and f). IRX-2-mediated blocking of MV-induced apoptosis was time dependent, as extending the time of the preincubation with IRX-2 intensified its protective
Figure 1 Preincubation with IRX-2 decreases CD8
þ Jurkat cell apoptosis induced by various agents. CD8 þ Jurkat cells were pretreated with IRX-2 (1 : 3 dilution B4 ng/ ml or 90 IU/ml IL-2) for 24 h and then treated with tumor-derived MV (10 mg), CH-11 Ab (400 ng/ml) or staurosporine (1 mg/ml) for 3 h. (Figure 1f) . At the highest possible concentration (i.e., undiluted IRX-2), IRX-2 completely inhibited the induction of apoptosis by MV (Figure 1f ). IRX-2 alone had no effect on Jurkat cell apoptosis.
IRX-2 protects T cells from MV-induced apoptosis at various steps of the apoptotic cascade. Next, the ability of IRX-2 to inhibit downstream steps in the apoptotic process was evaluated by co-incubating Jurkat cells with MV. We previously determined that the protection observed in this system was similar to that seen with primary T cells in response to several apoptosis-inducing agents tested. MV treatment of Jurkat cells led to a very strong increase in the mean fluorescent intensity (MFI) of caspase-3/-7-FAM, a dye that binds most efficiently to activated caspase-3 and caspase-7, the main effector caspases of both receptorand mitochondria-mediated apoptosis (Figure 2a and b) . Pretreatment of Jurkat cells with IRX-2 completely prevented the induction of caspase activity, similar to the irreversible caspase inhibitor, zVAD, and the anti-Fas neutralizing monoclonal antibody (mAb), ZB4. Caspase-3 activation in these cells by MV was also detected by western immunoblots, where a significant processing of the prodomain and a simultaneous increase of the active cleaved form (p18) was observed in MV-treated Jurkat T cells over 24 h (Figure 2c, lanes 3 and 4) . IRX-2 pretreatment effectively blocked the generation of the active subunit (Figure 2c , lanes 5 and 6).
In addition, IRX-2 blocked the MV-induced loss of MMP in Jurkat T cells (Figure 2d and e). This effect was similar to that mediated by the two inhibitors z-VAD and ZB4 (Figure 2e ), although zVAD-mediated inhibition was partial, even when high concentrations (up to 100 mM) were used. This result suggests that MV may also induce mitochondrial depolarization in a caspase-independent manner. Finally, IRX-2 pretreatment significantly reduced the MV-induced nuclear DNA fragmentation as detected by TUNEL assays ( Figure 3A and B), representing an advanced step in the apoptotic process. We have, therefore, confirmed that the protective effect of IRX-2 impacts many of the relevant steps that culminate in MV-mediated T-cell death.
IRX-2 does not reverse MV-induced apoptosis. To determine whether IRX-2 could protect T cells from apoptosis once the apoptotic cascade had been initiated, CD8
þ Jurkat cells were treated first with MV and then incubated with IRX-2. Alternatively, Jurkat cells were simultaneously treated with MV and IRX-2. In comparison to the effects of IRX-2 treatment before the addition of MV, apoptosis was reduced by about 50% after simultaneous coincubation of T cells with MV þ IRX-2 ( Figure 3C ). When IRX-2 was added 3 h after treatment with MV, the protective effect of IRX-2 was completely abrogated. IRX-2 was not able to inhibit the apoptotic cascade already initiated in T cells by MV. Thus, it appears that IRX-2 acts through a protective mechanism and cannot induce a reversal of apoptosis once it is initiated by MV.
IRX-2 protects T cells from both apoptotic pathways. To further examine the mechanisms responsible for IRX-2-mediated protection of T cells from MV-induced apoptosis, we performed western blots using cytosolic and heavy membrane (mainly mitochondrial) cell fractions. As shown in Figure 4 , MV-induced mitochondrial release of intermembrane apoptogenic proteins (cytochrome c, SMAC and AIF). The appearance of cytochrome c and SMAC in the cytosol was associated with their reduced levels in the mitochondria-containing fraction. IRX-2 effectively inhibited mitochondrial release of these proteins. Cleavage of Bid and mitochondrial translocation of tBid were also inhibited in cells pretreated with IRX-2. Moreover, cleavage of caspase-8 by MV into p43/41 and p18 fragments in the cytosol was also inhibited by IRX-2. Antiapoptotic proteins, Bcl-2 and Bcl-XL, were not decreased by short-term MV treatment in mitochondria, although pretreatment with IRX-2 appeared to increase their expression. In contrast, when primary activated CD8 þ T cells were used, MV induced significant downregulation in Bcl-2, Bcl-XL and FLIP expression, whereas IRX-2 pretreatment in part prevented their loss, as demonstrated by quantitative flow cytometry ( Table 2) . The difference between flow and western blot results in antiapoptotic protein expression may be due to the use of different methods applied to different cell types. In any case, MV caused a significant upregulation of the proapoptotic proteins Bax and Bim, which was prevented by IRX-2 pretreatment (Table 2 ; Supplementary Figure 1 ). Although MV alone increased Fas expression on Jurkat or primary T cells, IRX pretreatment decreased (Po0.002) Fas expression on the surface of these cells (data not shown). MV and IRX had little or no effect on the expression of Experiments were also performed to evaluate effects of cycloheximide on IRX-2-mediated protection of T cells. IRX-2 protection was significantly reduced in the presence of cycloheximide (Po0.002), and this reduction was accompanied by downregulation in expression levels of FLIP, Mcl-1 and Bcl-2 (data not shown). The Akt/PI3K pathway is the main downstream target of antiapoptotic activity of IRX-2. Because our findings showed a substantial influence of IRX-2 on several key proteins of the Bcl-2 family, which could be regulated by the Akt/PKB signaling pathway, we measured the activation of Akt-1/2 in response to MV and/or IRX-2 by western blots. Preincubation with IRX-2 did not enhance basal Akt phosphorylation (Figure 5b, compare lanes 1 and 2) . However, when the cells were treated with MV, a dramatic, time-dependent dephosphorylation of Akt-1/2 was observed ( Figure 5b, panel 1, lanes 3 and 4) . A time-course study with 10 mg of MV showed that Akt dephosphorylation started at 3 h of incubation and intensified over time (data not shown). Figure 5c , pretreatment of Jurkat cells with the Akti-1/2 inhibitor before IRX-2 and MV treatments resulted in a gradual abrogation of the antiapoptotic effect of IRX-2. At a relatively low inhibitor concentration of 1 mM, the protection from apoptosis provided by IRX-2 was only slightly inhibited. However, it was completely blocked at the inhibitor concentration of 5 mM. At these inhibitor concentrations, cell viability was not affected. In addition, the inhibitor significantly increased Bax levels and decreased expression levels of Bcl-2 and FLIP (Po0.02 for all) in Jurkat cells exposed to MV and IRX-2 (data not shown). In aggregate, these findings strongly suggest that Akt may be the main downstream coordinator of the survival signal provided by IRX-2, by modulating expression levels of antiand proapoptotic proteins.
IRX-2 protects T cells from MV-induced downregulation
The survival signals promoted by IRX-2 are comparable to protective effects of IL-2, IL-7 and IL-15. Because IL-2 is a principal cytokine in IRX-2, the observed antiapoptotic activity of IRX-2 could be largely IL-2 dependent. However, synergy with other cytokines present in IRX-2 could promote survival. Activated primary CD8 þ and CD4 þ T cells were incubated with IRX-2 or 100 IU/ml of recombinant human IL-2, a dose approximating that present in IRX-2 (at 1 : 3 dilution) and compared for the ability to inhibit MV or CH-11 Ab-induced apoptosis. As shown in Table 3A , IL-2 had a similar protective effect against MV-induced apoptosis as IRX-2 in CD8 þ T cells, but had a somewhat lower, although still significant, protective effect in CD4 þ T cells. In terms of protection against CH-11 Ab-induced apoptosis, IL-2 was significantly less effective than IRX-2 in enhancing survival of CD4 þ T cells and had almost no effect in CD8 þ T cells (Table 3B ). These findings indicate that the survivalenhancing potential of IRX-2 is greater than that of its main cytokine IL-2 and that support by other cytokines present in IRX-2 at very low physiological concentrations might contribute to these effects.
In addition, we compared the protective effect of IRX-2 with the activity of recombinant IL-7 and IL-15, both potent survival cytokines for T lymphocytes, which are not present in the IRX-2 mixture. Preincubation of T cells with these cytokines at a concentration of 10 ng/ml, alone or in combination, provided protection from MV-or CH-11 Ab-induced apoptosis in all cases, although to a different extent (Table 3A and B) . A combination of both cytokines blocked apoptosis in the CD8 þ and CD4 þ cell subsets, and the level of apoptosis inhibition was similar to that mediated by IRX-2, but only in case of MV-induced apoptosis (Table 3A and B) . Thus, the protective effects of IRX-2 were comparable to or in some cases (e.g., protection of CD8 þ cells) even stronger than those of the recombinant survival cytokines, IL-7 and IL-15.
Discussion
One of the mechanisms used by human tumors to escape from the host's immune system involves targeted elimination of CD8 þ effector T cells through apoptosis mediated by tumor-derived MV. 15, 16 Immunosuppressive MV have been found in neoplastic lesions, sera, ascites and pleural effusions obtained from cancer patients and have been linked to apoptosis and TCR alterations in effector T cells in these patients. 16 MV-driven elimination of effector T cells, which are necessary for antitumor host defense, might contribute to cancer progression. Therefore, protection of antitumor effector cells from functional impairments and death is a major objective of immune therapy. Clinical and experimental data show that certain cytokines, especially survival cytokines using the common receptor g-chain, are able to protect activated T cells from tumor-induced death and enhance their antitumor activity. 17 A new biologic agent called IRX-2 contains natural cytokines and growth factors produced by ex vivo stimulated human peripheral blood mononuclear cells (PBMC) under cGMP conditions. In the initial clinical studies with HNSCC and cervical carcinoma patients, immunotherapy with IRX-2 led to immune-mediated tumor regression in some of these patients. 12, [18] [19] [20] In HNSCC patients treated with IRX-2, tumor regression was accompanied by extensive leukocyte infiltrates. These local changes were, in turn, accompanied by a delayed tumor recurrence and an increase in overall survival as compared to historical controls. 12, 21 Another effect of IRX-2 was the restoration and normalization of lymphocyte counts in preclinical studies in mice and in lymphopenic HNSCC patients, respectively, especially in combination with thymosin-a1. 20 In the current study, we asked whether IRX-2 is additionally able to protect T cells from apoptosis mediated by tumorderived MV. Using a previously established in vitro model of 11 we demonstrated that IRX-2 provides strong protection to T cells from apoptosis mediated by tumor-derived MV through activation of survival pathways, thereby effectively counteracting cancer-related immunosuppression. The PI3K/Akt pathway is known to have a key function in T-lymphocyte survival through the regulation of 44.2 ± 6.9 -31.7 ± 3.0 0.0128 a Activated primary CD8 + and CD4 + T cells were preincubated with IRX-2 (1 : 3 dilution), recombinant human IL-2 (100 IU/ml), IL-7 (10 ng/ml), IL-15 (10 ng/ml) or IL-7 and IL-15 (both 10 ng/ml) for 24 h and then treated with 10 mg MV or 400 ng/ml CH-11 Ab for an additional 24 h. Activation of caspases was analyzed by flow cytometry. The data are mean percentages of FITC-VAD-FMK+ cells ± S.D. obtained in three independent experiments.
b The P-values refer to significant differences between cells pretreated with IRX-2 compared to MV alone or cells pretreated with the indicated cytokine compared to those pretreated with IRX-2.
c The P-value refers to the difference in sensitivity to MV-mediated apoptosis between CD8 + and CD4 + T cells pro-and antiapoptotic proteins including Bcl-2 family members. 22 We confirmed that the effects of IRX-2 on some of the Bcl-2 family members as well as cFLIP were mediated by the PI3K/Akt pathway. Tumor-derived MV caused a dramatic time-dependent Akt dephosphorylation and IRX-2 pretreatment completely inhibited the MV-induced inactivation of Akt. Our preliminary data show that the Akti-1/2 inhibitor eliminates protective effects of IRX-2 and this is accompanied by a significant downregulation of Bcl-2 and FLIP expression levels as well as upregulation of Bax expression in Jurkat cells (data not shown). These data support the hypothesis that the PI3K/Akt pathway is a central target of IRX-2 for regulating T-cell survival.
IRX-2-mediated protection of activated T cells extends to apoptotic signals induced by agents other than tumor-derived MV, for example, CH-11 Ab or staurosporine. Because the former induces apoptosis mainly through the death receptor pathway 23 and the latter activates only the mitochondrial pathway, 24 these findings suggest that IRX-2 can protect T cells from both the extrinsic and the intrinsic death pathways. Indeed, it appears that MV initiate caspase-8-dependent apoptotic cascade in association with the production of a proapoptotic Bid fragment. As a BH3-only protein, tBid translocates to the mitochondria, and either activates Bax directly 25 or binds and neutralizes antiapoptotic Bcl-2 family members, Bcl-2, Bcl-XL and Mcl-1. 26 Binding of tBid to antiapoptotic Bcl-2 proteins may interfere with their interaction with Bax. 27 The MV-mediated activation of caspase-3 could represent the combined effect of direct processing of caspase-3 by caspase-8, and further activation of caspase-3 downstream of the mitochondria following the release of the apoptogenic proteins. The significant loss in Mcl-1 expression level may result from its degradation by caspase-8 and caspase-3. 28 Because IRX-2 appears to inhibit the MV-mediated activation of caspase-8, it may indirectly block many of the downstream apoptotic events, including Bid cleavage, release of mitochondrial intermembrane apoptogenic proteins and activation of effector caspases. Our data further suggest that the antiapoptotic effect of IRX-2 is not limited to its inhibition of caspase-8 activation, as it independently increases expression levels of antiapoptotic Bcl-2 proteins. Of note, upregulation of Mcl-1 by IL-2, IL-15 and IL-7 has been previously reported. 29 Thus, IRX-2-mediated protection appears to be a generalized phenomenon, which is accompanied by upregulation of the antiapoptotic Bcl-2 family members. These results are consistent with numerous other studies reporting changes in Bcl-2, Bcl-XL or Bax expression in circulating T cells of patients with different malignancies, 30, 31 potentially implicating tumor-derived MV in this process.
In addition, we noted that pretreatment of T cells with IRX-2 partially counteracted the MV-induced downregulation of cFLIP, a dominant-negative inhibitor of caspase-8, and a central modulator of Fas-induced apoptosis. 32 It can block the intrinsic mitochondrial pathway indirectly through induction of NF-kB and TCR-induced and IL-2-mediated downregulation of cFLIP has been correlated with the sensitivity of T cells to activation-induced cell death. 33 Our preliminary data indicate that FLIP expression levels have a function in IRX-mediated protection of activated T cells from apoptosis.
A principal cytokine in the IRX-2 immunotherapeutic product is IL-2, and it was possible that IL-2 was primarily responsible for the observed cytoprotective effect of IRX-2. However, IRX-2 was found to be significantly more effective than IL-2 alone in enhancing survival of activated human CD8 þ and CD4 þ T cells. It is likely that cytoprotective effects of IL-2 in IRX-2 are enhanced by the presence of IFNg and GM-CSF, which in combination, could mediate immunopotentiating effects. 30 The function of other components of IRX-2 (e.g., IL-1a, IL-6, IL-8, TNFa) in promoting T-cell survival is less clear, although studies have shown that depending on tissue location and concentration some of these proinflammatory cytokines can also support antitumor immune responses. 30 It is important to note that a functional synergism among the various components of IRX-2 was previously described, demonstrating, for example, that IRX-2 was able to induce maturation of DCs to a greater extent than comparable levels of TNFa alone. 13 Cytoprotective effects of IRX-2 were compared with those mediated by the survival cytokines, IL-7 and IL-15, which, like IL-2, are members of the common cytokine receptor g-chain family. They are important in the peripheral T-cell homeostasis and maintenance of memory T cells. 31 IRX-2 was found to be significantly more effective than recombinant IL-7 in protecting activated CD4 þ and CD8 þ T cells from MV-and CH-11 Ab-induced apoptosis and had similar protective effects as IL-15. Among the cytokines tested, IRX-2 had the greatest survival potency when CH-11 Ab was used to induce apoptosis, implying protection against receptor-mediated apoptosis.
Because it is acknowledged that the common cytokine receptor g-chain mediates survival signals through the JAK3/ STAT5 pathway in T cells, 34 effects of MV and IRX-2 on the expression and activation of JAK3 and STAT5 were also evaluated. As expected, a significant downregulation of JAK3 expression by MV was observed. 14 IRX-2 was able to restore MV-induced JAK3 downregulation completely, although it did not increase its baseline expression. IRX-2 also induced strong activation of STAT5 proteins that are important survival factors, required for the protection of mature T cells from apoptosis. 34 Further, MV-mediated downregulation of CD3z, a key signaling molecule of the TCR pathway, in T cells was prevented in the presence of IRX-2. Together, these data emphasize the key function that cytokines present in IRX-2 have in the regulation of death and survival in activated T cells.
Overall, our study indicates that the pretreatment of T cells with IRX-2 restores the balance between pro-and antiapoptotic Bcl-2 family proteins and normalizes the expression of cFLIP, JAK3 and CD3z, using the PI3K/Akt pathway as the key regulator. The mechanism of protection mediated by IRX-2 includes neosynthesis of a survival protein that is under the control of the Akt pathway, as Akti-1/2 inhibitor abolished protection and at the same time, decreased expression levels of antiapoptotic proteins but upregulated that of proapoptotic Bax. This mechanism provides potent protection of activated T cells from tumor-induced death, inhibiting the Fas-mediated as well as the mitochondrial pathway of apoptosis. As effector T cells resistant to immunosuppressive influences of the tumor microenvironment are essential for antitumor host defense, utilization of IRX-2 in cancer immunotherapies is likely to improve their survival and promote antitumor effects significantly.
incubated with the optimal dilution of each Ab for 20 min at RT in the dark, washed twice with staining buffer and finally fixed in 1% (v/v) paraformaldehyde (PFA) in PBS. The following Abs were used for surface staining: anti-CD3-ECD, anti-CD4-PE, anti-CD8-PC5, anti-Fas-FITC and anti-FasL-PE. The appropriate isotype control Abs were used in all experiments.
Flow cytometry. Four-color flow cytometry was performed using a FACScan flow cytometer (Beckman Coulter) equipped with Expo32 software (Beckman Coulter). Lymphocytes were gated based on morphology, and debris, MV as well as monocytes and granulocytes were excluded, collecting data on at least 10 5 cells. For the analysis of activated primary T lymphocytes, gates were restricted to the CD3 þ CD8 þ or CD3 þ CD4 þ T-cell subsets. Data were analyzed using Coulter EXPO 32 version l.2 analysis software.
Annexin-V-binding assay. Annexin V binding to MV and/or IRX-2 co-incubated CD8
þ Jurkat cells or activated T lymphocytes was measured by flow cytometry to evaluate spontaneous or in vitro induced apoptosis. Following surface staining with antibodies to CD3, CD8 or CD4, the cells were resuspended in ANX-binding buffer and incubated with FITC-conjugated ANX for 15 min on ice. Additional staining with 7-AAD was performed to discriminate dead and live cells. Routinely, fewer than 10% of cells were 7AAD
þ . The cells were analyzed by flow cytometry within 30 min of staining.
Measurement of caspase activation. Pan-caspase activity was tested by intracellular staining of activated caspases using a pan-caspase inhibitor, CaspACEt FITC-VAD-FMK In Situ Marker (Promega, Madison, WI, USA). Cells were resuspended in PBS and FITC-VAD-FMK was added at a final concentration of 5 mM. The cells were incubated for 20 min at 371C, 5% CO 2 and washed with PBS. Then cells were stained for cell-surface receptors, fixed with 1% PFA and analyzed by flow cytometry. The specific activation of caspase-3 and caspase-7 was measured using the Vybrant s FAM caspase-3 and -7 Assay Kit from Invitrogen (Carlsbad, CA, USA) according to the manufacturers' instructions. Briefly, cells were resuspended in PBS and stained with a 150 Â dilution of the carboxyfluorescein (FAM)-labeled FMK-caspase inhibitor for 60 min at 371C, 5% CO 2 . Then the cells were washed in wash buffer and fixed with 1% PFA. The cells were analyzed by flow cytometry with the fluorescein measured on the FL1 channel.
Measurement of the mitochondrial membrane potential. The loss of MMP as a hallmark of apoptosis was measured using the MitoProbet JC-1 Assay Kit from Invitrogen. The cationic dye JC-1 (5, 5 0 , 6,6 0 -tetrachloro-1,1 0 , 3, 3 0 -tetraethylbenzimidazolylcarbocyanine iodide) exists in healthy cells as a green monomer in the cytosol and also accumulates as red aggregates in the mitochondria. In apoptotic and necrotic cells, JC-1 remains only in the cytoplasm due to mitochondrial depolarization, which can be detected by flow cytometry as a decrease in the red/green fluorescence intensity ratio. CD8 þ Jurkat cells or activated T lymphocytes were incubated in PBS containing 2 mM of JC-1 for 30 min at 371C, 5% CO 2 . An aliquot of the cells was treated with 50 mM of the mitochondrial uncoupler carbonyl cyanide 3-chlorophenylhydrazone (CCCP) during the staining period as a positive control for mitochondrial depolarization. The cells were analyzed using a flow cytometer immediately after staining.
Evaluation of apoptosis-related proteins. Expression of antiapoptotic proteins Bcl-2, Bcl-xL, FLIP and Mcl-1 and the proapoptotic proteins Bax, Bim and Bid was investigated in CD8 þ Jurkat cells or activated primary T lymphocytes using multicolor flow cytometry. The cells were first stained for surface T-cell markers as described above. For intracellular staining of apoptosis-related proteins the cells were fixed with 1% (v/v) PFA in PBS at RT for 10 min and then permeabilized with saponin (0.1% v/v in PBS) for 15 min at 41C. Next, the cells were stained for 30 min at 41C with FITC-or PE-conjugated antihuman Bcl-2, Bax and Bcl-xL or unconjugated antibodies specific for FLIP, Bim, Bid or Mcl-1, followed by a wash with 0.1% saponin. Samples stained with unconjugated antibodies were further incubated with an FITC-conjugated goat anti-rabbit IgG for 15 min at RT. After washing with 0.1% saponin, cells were fixed in 1% (v/v) PFA. Isotype controlmatched antibodies were used for both surface and intracellular controls and all antibodies were pretitered on fresh PBMC. In some experiments, Jurkat cells were preincubated with cycloheximide at the concentration of 1 or 10 mg alone or with MV þ IRX þ CHX and expression levels of pro-and antiapoptotic proteins as well as Annexin V binding to Jurkat cells were measured.
TUNEL assay. DNA fragmentation was measured using the In Situ Cell Death Detection Kit, TMR red (Roche, Indianapolis, IN, USA). Briefly, cytospin preparations (100 000 cells per slide) of MV-and IRX-2-treated T cells were airdried and fixed with 4% (v/v) PFA in PBS for 1 h at RT. Slides were rinsed with PBS and incubated with permeabilization solution (01% Triton X-100 in 0.1% sodium citrate) for 2 min on ice. Then the slides were washed twice with PBS and incubated with 20 ml of the TUNEL reaction mixture for 1 h at 371C in a humidified chamber in the dark. Then the samples were washed extensively with PBS and incubated in a medium with 4 0 ,6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA, USA) to trace cell nuclei. Slides were evaluated in a Nikon Eclipse E-800 fluorescence microscope under Â 200 magnification. For digital image analysis, Adobe Photoshop 6.0 was used. A minimum of 300 cells were randomly counted in a microscopic field to determine the percentage of cells with DNA fragmentation.
Statistical analysis. Statistical analysis was performed using the Student's t-test. P-values o0.05 were considered significant.
